All right, we're going to discuss Atomo's first quarter results. We're pleased to see our chairman and shareholders on the call today. Welcome. We've received a few questions ahead of the call, which I will answer as I go throughout the presentation, and I'll try to specifically address them as we go. At the end, we'll take a few more questions. Please feel free to enter them during the call. I now have 10 weeks behind me as the CEO, and I'm happy to report that we've hit the ground running to advance the current partnerships, to add new ones, to accelerate new revenue streams through additional product development opportunities. I would direct you to read our disclaimer, which is included in our result materials. We were very pleased with our first quarter results. First, we made significant advances in our product pipeline. These are important because they will lead to additional revenue streams as they get to market. In terms of pipeline advances, we have moved the program forward and the supply agreement discussions to the point where our partner, Upfront Diagnostics, agreed to announce our partnership. This was the U.K. partner previously discussed. Their product for brain injury and stroke is a really exciting opportunity. There was a question submitted about whether we might sign the supply agreement, and although there are no guarantees on the timing, our goal is to get this done before the end of this calendar year. We're excited to announce a partnership with Innovation Scientific to add Gen 4 HIV to our proprietary product development pipeline. I'll provide some more clarifications on this agreement later in the presentation. Finally, our active syphilis product completed tech transfer for Burnet into our manufacturing at Atomo. Now this product can be manufactured as we prepare for our upcoming clinical trials. Financially, it was a strong quarter. Revenue increased 140% over the previous year's quarter to reach AUD 1.63 million, and this was driven by growth of over 38% in our HIV franchise and more than 450% growth in our OEM business. There was a question on whether we had revenue from FebriDx in the quarter, and the answer is clearly yes, we did. We had a strong collection quarter and ended with AUD 2.5 million in cash, and we remained debt-free. Our HIV franchise continues to perform well. We posted more than 38% growth in the quarter, and this was driven by both our international business and growth of our direct pharmacy business in Australia and New Zealand. Our OEM business grew more than 450%, and this was driven by FebriDx. I won't steal Lumos Diagnostics' thunder, but they've reported going live in more than 200 sites in the U.S. Like everyone, we are excited to see their success as the flu season progresses. One of our highest priorities has been to drive future value for Atomo shareholders, and by adding more products to our proprietary pipeline and to advance them to market as rapidly as possible. We announced a partnership with Innovation Scientific for Atomo to rapidly bring a Gen 4 HIV product to market, building on our Gen 3 success with synergies with our active syphilis product. If all goes well, we expect syphilis and Gen 4 products to be launched around the same time, with registrations completed in about 18 months. There seem to be some questions about the partnership, so I'd like to provide a little more color on these. Atomo will license the proven innovation for the Innovation Scientific Gen 4 strip for use in our Galileo cassette. This is similar to what we've done with Burnet in terms of licensing their active syphilis and their liver ALT strips. Innovation Scientific will also act as our contract manufacturer, assembling the Galileo cassettes with the strips and doing the final packaging. Atomo will continue to use its current partners to mold the Galileo sub-assemblies. Atomo and many small companies in the medical device industry use partners to mold parts and to augment assembly and packaging capabilities. The agreement with Innovation Scientific is no different from the other agreements that Atomo has with these other providers. We expect to negotiate and sign a final development supply agreement and license over the coming months and to move forward with analytical and clinical trials in the second half of the fiscal year. There was a question about what's the difference between a Gen 3 and a Gen 4 HIV test. Technically, the Gen 3 test looks at the antibodies to HIV, which means it's evidence that there has been an infection by HIV. The Gen 4 includes the same antibody, but it also detects an HIV-specific protein, p24. This is a viral protein that can appear in the blood before antibodies develop. Atomo's Gen 3 test is a strong screening test that can easily and cost-effectively identify HIV infection. It is recommended to have a confirmatory test afterwards. Atomo has made a big difference globally in public health, developing nations, and self-testing applications with our Gen 3 test. Many Gen 4 tests can detect HIV earlier and in a more robust fashion. It's typically more of a professional-use product, clinical and primary care applications. It can also be for the same self-test markets and screening markets where the pricing supports the product. Overall, HIV remains a large and growing market opportunity with more than AUD 1 billion spent on rapid tests annually. Gen 4 builds upon our Gen 3 franchise, and is also a good fit with our active syphilis product. We are also excited to reveal our U.K. partner for brain injury and stroke applications, Upfront Diagnostics. Their LVOne first-generation product recently received CE marking. Our partnership is around their next-generation product, LVTwo, which will be in our proprietary device. It will bring that extra ability, usability, and performance to their assay. When you start talking about emergency settings, not having to fool around with bottles and mixing reagents, but be able to do the lance, collect the blood, and release the buffer all in one device will enable these emergency situations. As I mentioned previously, we hope to sign the supply agreement by the end of the year. The brain injury and stroke markets are quite significant, and tests like LVTwo could have a huge impact on the patients and getting them the treatment that they need in the rapid time frames that they need to make a difference. The stroke market alone is nearly a AUD 12 million opportunity. We are very excited about our active syphilis product. It continues to post exciting performance results. It's shown 100% sensitivity, 99% specificity for infected patients, 93% sensitivity against previously treated with clinical history patients. We are excited that we've been able to transfer the technology from Burnet to our manufacturing site, and we are now actively producing products that will be used for analytical and clinical studies going forward. Atomo is a commercial stage diagnostic company with a growing pipeline of new products. Our proprietary Gen 3 franchise is growing well, more than 38% in the quarter. In the second half of this year, we are focused on building more distribution partnerships to drive more sales on a global basis. As we have been discussing, Gen 4 will enter analytical and clinical testing in the near term and will expand Atomo's current franchise. Active syphilis is rapidly advancing through the pipeline. Both Gen 4 and active syphilis have overlapping markets and are expected to reach the market in 18 to 24 months if all goes as planned. We are also excited about our ALT liver product and exploring feasibility around hepatitis B and hepatitis C. This is how we are going to add more value for Atomo shareholders, by increasing the number of assays that Atomo can take to market to add additional revenue streams and earnings. We are layering products upon product, and that is how we are going to build a high-value, high-growth diagnostic business. Atomo also captures revenue through its partner assays. FebriDx is the most well-known product in our OEM pipeline, recently getting FDA approval and receiving CLIA waiver in the spring. It highlights the 99% concordance between professional laboratory users and non-professionals. Our partnership with NG Biotech around pregnancy is well-known. The product has been in the market, and we see increasing opportunities there as well. We have announced our development programs with Chromacare for ferritin and Upfront Diagnostics for brain injury. There was a question on when we will sign the supply agreements with both Upfront and Chromacare, and as I mentioned, we are actively working on those and trying to close those by the end of the year. For the financials, I am going to pass it to Susie to provide us an update, but overall, we had a very strong quarter. Thanks, Sherry, and thank you all again for joining us for our quarterly update. Jumping into our results for the quarter, Q1 delivered strong top-line revenue growth with revenue increasing 140% to AUD 1.63 million. This was supported by a continued momentum, as Sherry mentioned, from HIV sales, up 38% quarter-on-quarter, reaching AUD 630,000 in sales, and particular strong growth in our OEM revenue of AUD 938,000, which was four and a half times growth quarter-on-quarter. Gross margin was 26% compared with last year of 38%. Again, this was reflecting the mix of revenue recognized during the quarter. Looking down the table to operating expenditure, operating expenditure increased to AUD 1.98 million, and EBITDA was AUD 1.3 million loss there, and that was compared with last year of AUD 983,000 loss for prior year. The increase in operating expenditure is particularly reflected by, is partly reflected by our CEO transition costs and regulatory costs, but more importantly in the continued investment in the commercial and product development capabilities and revenue-generating activities to position the company for future growth and scalability. While the increased revenue has not translated yet into EBITDA improvement, we saw a substantial step-up in revenue growth and gross profit. The focus is now on improving the margin contribution from that growing revenue base and driving greater operating leverage. Now turning to the balance sheet. Our balance sheet remains relatively consistent with the position that we presented at 30 June, with no significant changes to highlight. We have ended the quarter with AUD 2.67 million in cash and continue to carry no debt on the books. This brings me to the cash flow activities for the quarter. Our overall receipts for the quarter totaled AUD 2.5 million, and that was made up of AUD 2.4 million from customer receipts and a further AUD 84,000 from the syphilis grant milestone payment. On the outflow side, total cash outflows to suppliers and employees was AUD 3.4 million, bringing us to end on the quarter of AUD 2.6 million with cash in hand and no debt. That is pretty much our wrap-up for the quarterly numbers. On that note, I will hand back to Sherry for wrap-up and QA. Thanks, Susie. In closing, Atomo is building a stronger base for scalable growth. The current business is doing well. Revenue grew 140% year over year, driven by our HIV franchise and the success of our partners. We are building diversification through adding new proprietary products to the pipeline and advancing our own products as well. With that, we will end the presentation. We would like to invite you to our annual general meeting that is being held later this week on November 5th. I look forward to seeing you there. Before we close, we will take some questions. I do have a few here that I did not address in the presentation, but were submitted beforehand, so I will go ahead and walk through those. The first was, "Could you elaborate on Atomo's strategic direction and entry with respect to HIV product in Fiji?" We do have a multi-pronged effort working through the different constituents to help solve this crisis. As everyone knows, it is a big humanitarian crisis in Fiji, but we are also looking at how we can help across Oceania, and hopefully we will be able to report back more in future days. We had another question about our gross margins and why do we have a gross margin decline. What actions are being taken to scale while improving and not decreasing margins, specifically containing or lowering per-unit cost of manufacturing and lowering cost of sales and revenue growth? We, of course, are also very interested in improving our gross margins and also getting more leverage out of our operating model as well in this quarter. When you see different quarters, the variation, it's really driven by the blend of revenue. Our business is still lumpy, and different businesses have different margin contributions, and these are based on historical relationships and contracts that are in place. There are several layers of things that we're doing actively to make some positive impacts. The first is we're increasing the revenue diversification with higher-margin revenue streams, and as we add more revenue sources, that will take away some of this lumpiness and the swings in the gross margin. We're bringing on new products that are focused on professional use. These carry higher pricing and also better gross margins, as you can imagine. This is different than the previous focus on public health products, which typically carry lower margins. We are making significant investments in high cavitation molds and also taking our blister production machine in-house. We're in the tail end of those processes, and we should start seeing that bear fruit as we move into the second half of the year. That should yield better per-unit costs as we go forward. Then finally, there's two final questions. "When will Atomo become cash flow positive?" Atomo runs a very lean team for a commercial diagnostic company. We are making investments in new products and the things we've talked about to improve our gross margins going forward as we launch new products, so the Gen 4 product, the active syphilis product, the new partnership products for ferritin and brain injury. As FebriDx grows, we expect to reach an inflection point to break even. Currently, these investments are critical to drive the diversification of revenue necessary to cover the company's operating costs. From all reports received, Atomo Diagnostics is making good progress on product development and expanding markets. Since purchasing shares around 2020, I have always had a positive view of Atomo. Why do you think the market does not value Atomo more highly in its share price?" I think a lot of us on this call are frustrated by the situation as well. We are a commercial diagnostic company with a differentiated platform, and it does provide superior usability and performance for rapid blood-based testing. We are successfully adding new products to our pipeline. This has been a really big push by the whole team and the board over the last 18 months. It's really starting to pay off now. We have active syphilis and liver test and Gen 4 in our pipeline. So really a lot of exciting things going on. We're also seeing our partners progress their products. FebriDx has come to market. The ferritin project and the brain injury products are also progressing through their processes. So we're really excited about all of that. There's still, I think, a ways to go to build enough awareness for Atomo on a global basis with the funds and with new shareholders that will really get excited about the Atomo story. If you look at how we're trading, we're trading below 2.4 times our trailing 12-month revenue, which is very low compared to other companies in the space with the same kind of pipelines and opportunities for future growth that Atomo has. I think at this point, it's a really great value for investors, and we need to do a better job of doing the work on the investor relations side, educating funds and shareholders on what we're doing, why we're doing it, how we're doing it, what our strategic focus is going forward, and then really why an investment now makes sense. But it is definitely a focus that we're committed to going forward. Hopefully, it doesn't help that the microcap market is struggling a bit overall on the ASX as well. Hopefully, as you probably saw in the announcement, I've agreed to stay through the full year, so through August of 2027. Then I think as we get towards the end of that time, the board will make some decisions and actions. Yeah, I think that was the only live question coming through for that slide. Okay, great. We appreciate all of your time today and look forward to seeing you at the AGM. Thanks all.